- Home
- USEA vs HOTH Comparison
USEA vs HOTH Comparison
Compare USEA & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | HOTH |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 16.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | USEA | HOTH |
|---|---|---|
| Price | $1.85 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 72.5K | ★ 513.3K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,025,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.66 |
| 52 Week High | $2.22 | $2.12 |
Technical Indicators
Market Signals| Indicator | USEA | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 44.13 |
| Support Level | $1.69 | $1.00 |
| Resistance Level | $1.85 | $1.13 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 90.87 | 31.08 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).